

Index

- 5-fluorouracil, 121
- 5HT. *See* serotonin
- acrosome, 18
- acrosome reaction assessment, 55
- actinomycin-d, 121
- activins, 81
- adenomas, pituitary, 155–6
- adoption, 286–7
- agglutination, 26, 30–1, 53
- aging, hypogonadism and, 82–3
- alcohol consumption, 43
- alkylating agents, 115, 120, 153. *See also* chemotherapy; *specific drugs*
CNS tumor treatment, 123
- alpha-1 adrenoreceptor antagonists, 74
- alpha-blockers, 75
- anabolic steroids, 43, 267–8
- anastrozole, 295
- androgen binding protein (ABP), 265
- androgen deficiency, 266. *See also* hypogonadism; testosterone varicocele effects, 65
- Androgen Deficiency in the Aging Male questionnaire, 87
- androgen insensitivity, 60
- androgen therapy, 296–7
- anejaculation (AE), 73–4. *See also* ejaculatory dysfunction
idiopathic, 244
neurogenic, 244
reproductive outcomes, 317
- anorgasmia, 244
- anthracyclines, 121
- anti-androgens, 84
- anti-epileptic drugs (AED), 150–1
- antimetabolites, 121
- anti-Müllerian hormone (AMH), 331
- antioxidant supplements, 195–6, 297.
See also dietary supplements
- anti-sperm antibodies (ASA), 30–1, 53, 299
- antral follicle count, 331
- Arimidex, 269
- aromatase inhibitors, 295
- assisted hatching (AH), 336–7
- assisted reproductive technology (ART), 329. *See also specific techniques*
complications, 339–40
ectopic pregnancy, 339–40
multiple gestations, 339
ovarian hyperstimulation syndrome (OHSS), 339
perinatal outcomes, 340
- asthenospermia, 28, 53
causes, 53
differential diagnosis, 53
- astrocytomas, 152, 154
- autoimmune diseases, 42
- autologous endometrial co-culture (AECC), 337
- azoospermia, 27, 58
chemotherapy effects, 113, 114
alkylating agents, 120
combination chemotherapy, 115–16
sperm retrieval, 316–19
classification, 58–9
etiogenesis, 27, 58
evaluation, 58–61
FSH measurement, 59
history, 58–9
physical examination, 59
semen analysis, 59
fertility options, 314
use of cryopreserved sperm, 314–15
non-obstructive, 27, 60–1
varicocele and, 307–8
obstructive, 27, 47, 59–62
- radiation therapy effects, 106–7
sperm retrieval, 319
reproductive outcomes, 317
treatment, 61–2
clomiphene citrate, 293–4
- barbiturates, 151
- benign prostatic hyperplasia (BPH)
retrograde ejaculation and, 75
- bevacizumab, glioma treatment, 154
- bicalutamide, 84
- birth defects, 174
- bladder neck
past surgery, 42
retrograde ejaculation and, 74–5
role in seminal fluid expulsion, 35
- bladder sperm harvesting, 77, 315–16
- bleomycin, 115–16, 121
- blood–testis barrier, 13, 299
breaching of, 30
- body composition, hypogonadism effects on, 86
- bone mineral density (BMD),
hypogonadism effects on, 85–6
- bone sarcomas, 125
Ewing sarcoma, 125
osteosarcoma, 125
- brain tumors, 150–2
gliomas, 152–5
meningiomas, 155
metastatic tumors, 158
pituitary tumors, 155–6
primary central nervous system lymphoma (PCNSL), 156–7
supportive treatment, 150–2
anti-epileptic drugs (AED), 150–1
corticosteroids, 151–2
- breast cancer, stimulation protocols, 277
- bromocriptine, 298
- bulbourethral glands, 7
role in seminal fluid emission
- busulfan, 120

- cabergoline, 298
- cancer. *See also* childhood cancer; female cancers; *specific types of cancer*
- azoospermia and, 60–1
 - fertility preservation importance, 224–7
 - sexual dysfunction relationships, 98
 - spermatogenesis and, 112–13
 - semen analysis in cancer patients, 31–2
 - varicocele and, 67–8
- cancer therapies, 45. *See also* chemotherapy; radiation therapy; *specific types of cancer*
- female cancers, 274–5
 - fertility preservation importance, 224–7
 - risks for future progeny, 226
 - sexual dysfunction relationships, 98
- capecitabine, 121
- carbamazepine, 151
- carboplatin, 113, 116, 120
- cardiovascular effects of
 - hypogonadism, 85
- carmustine, 120
- central nervous system tumors, 123
 - metastatic tumors, 158
- chemotherapy, 45, 110
 - agents, 115
 - alkylating agents, 120
 - antimetabolites, 121
 - classification, 114
 - cytotoxic antibiotics, 121
 - immunomodulators, 121–2
 - mitotic inhibitors, 121
 - platinum analogs, 120–1
 - topoisomerase inhibitors, 121
 - brain tumors, 152–3
 - temozolomide, 153–4
 - CNS tumors, 123
 - primary central nervous system lymphoma (PCNSL), 157
 - DNA damage, 116–17
 - effects on spermatogenesis, 255–6
 - combination chemotherapy, 115–16
 - versus radiation therapy, 113
 - fertility preservation, 145
 - fertility re-establishment, 146–7
 - gonadotoxicity and, 136–7
 - childhood cancer treatment, 162, 255–6
 - female cancer treatment, 274–5
- Hodgkin's lymphoma, 116, 129–31
 - hypogonadism and, 83–4
 - leukemia, 131
 - mechanisms of action, 113–15
 - neuroblastoma, 123
 - non-Hodgkin's lymphoma, 131
 - sarcomas, 124
 - Ewing sarcoma, 125
 - osteosarcoma, 125
 - sperm quality and use following treatment, 315
 - retrieval in azoospermic patients, 316–19
 - testicular cancer, 116, 145
 - Wilms' tumor, 123
- childhood cancer, 161, 255
 - adverse effects of treatment in later life, 161
 - fertility issues, 161
 - fertility potential following treatment, 163–4
 - fertility preservation, 164–8, 256–9
 - embryo cryopreservation, 235–8
 - ethical and legal issues, 168–9, 232–5
 - hormonal manipulation, 166–8
 - need to clearly state intentions, 238–40
 - options, 257
 - sperm cryopreservation, 164, 235–8, 256–7
 - stem cell autotransplantation, 257–8
 - stem cell culture, 258–9
 - testicular tissue harvesting, 164–6
 - gonadal toxicity following treatment, 161–3, 256
 - chemotherapy, 162, 255–6
 - effects of disease, 163
 - radiotherapy, 162, 256
 - solid tumors, 122–3
 - bone sarcomas, 125
 - central nervous system tumors, 123
 - neuroblastoma, 123
 - soft-tissue sarcomas, 124
 - Wilms' tumor, 123–4
- childhood illnesses and conditions, 41–2
- chlamydial infection, 298
- chlorambucil, 120
- chromosome abnormalities, 60
 - radiation therapy effects, 107
- cisplatin, 113, 116, 120
 - dosing, 114
 - gonadotoxicity, 114
- Clomid, 269
- clomiphene citrate, 43, 101, 293–4
 - hypogonadism management, 88–9
- clomiphene citrate challenge test (CCCT), 331
- coenzyme Q10, 196, 297
- cognitive appraisals, 190
- cognitive function, testosterone relationships, 86
- cohesion, 15–16
- communication
 - barriers to discussion, 172–4, 225, 261, 282–3
 - patient barriers, 173–4
 - counseling for donor insemination, 287
 - discussing sensitive topics, 283–4
 - facilitating provider discussion, 174–5
- computer-assisted sperm assessment (CASA), 28
- congenital bilateral absence of the vas deferens (CBAVD), 42, 61–2
- consent issues
 - childhood cancer, 168–9, 261
 - terminally ill and recently deceased patients, 322–4
- controlled ovarian stimulation, 276. *See also* ovarian stimulation with intrauterine insemination, 332
- coping strategies, 188
- corpora cavernosa, 7
 - smooth muscle physiology, 9
- corticosteroids, 121
 - brain tumor treatment, 151–2
 - immunological infertility treatment, 299
- countertransference issues, 192
- Cowper's glands, 7
- cryobiology, 214–15
- cryopreservation of embryos. *See* embryo cryopreservation
- cryopreservation of oocytes. *See* oocyte cryopreservation
- cryopreservation of sperm, 141, 172, 213, 232, 249, 331–2. *See also* fertility preservation; sperm banking
 - childhood cancer management, 164, 256–7
 - cooling rates, 217–18

Index

- cryopreservation of sperm (*cont.*)
 cryopreserved sperm use in
 azoospermic patients, 314–15
 cryoprotective agents (CPA), 216–17
 history of, 213–14
 importance for cancer patients,
 224–7
 indications, 221–4
 cryopreservation prior to cancer
 treatment, 224
 homologous and donor
 insemination, 221–3
 intra-operative cryopreservation,
 223
 post-operative cryopreservation,
 223
 premortem and postmortem
 cryopreservation, 223–4
 pre-operative cryopreservation,
 223
 media, 217
 protocols, 218–20
 freeze drying, 220
 vitrification, 219–20
 safety issues, 226–7
 semen extenders, 217
 semen screening, 220–1
 sperm collection techniques, 141–2,
 215–16. *See also* sperm retrieval
 storage costs, 241
 testicular cancer patients, 141–2
 thaw protocol, 218
 time limits for storage, 241
 tracking, 221
 versus embryo cryopreservation,
 235–8
- cryptorchidism, 41
 cyclophosphamide, 43, 113, 120
 dosing, 114
 gonadotoxicity, 114
 cyproterone acetate, 84
 cystic fibrosis (CF), 42, 61–2
 cytarabine, 157
 cytotoxic antibiotics, 121
 dacarbazine, 115, 120
 deceased patients. *See* postmortem
 sperm retrieval
 decision making, 190
 cognitive appraisals, 190
 emotional responses, 190
 moral judgments, 190
 deferential artery, 5
 depression, testosterone relationships,
 86
- dexamethasone, 151
 diabetes mellitus (DM), anejaculation
 and, 73
 dietary supplements, 195–6
 antioxidant supplements, 195–6,
 297
 coenzyme Q10, 196, 297
 folic acid, 196–7
 L-carnitine, 197
 omega-3 fatty acids, 197–8
 selenium, 198–9
 vitamin C, 199–200
 vitamin E, 198–9
 diethylstilbestrol (DES) exposure,
 43
 prostate cancer treatment, 84
 digital rectal examination, 47
 dihydrotestosterone (DHT), 265
 disorders of sex development (DSD),
 60
 DNA damage
 chemotherapy effects, 116–17
 radiation effects, 105, 107
 sperm DNA integrity tests,
 55–6
 donor insemination, 223. *See also*
 sperm donation
 donor guidelines, 222
 donor selection, 287–8
 history, 284–5
 recipient counseling, 287
 research, 286
 dopamine (DA), ejaculation
 regulation, 156
 dorsal nerve of the penis, 9
 double-stranded breaks (DSBs), 15, 16
 doxorubicin, 115, 121
 drugs. *See* medications; recreational
 drug use
 ectopic pregnancy, 339–40
 ejaculation. *See also* ejaculatory
 dysfunction
 anatomy, 71–2
 brain imaging studies, 156
 dribbling ejaculation, 37
 emission, 72
 expulsion, 72
 low volume ejaculate, 51–2
 neurochemical regulation
 dopaminergic control, 35
 oxytocinergic control, 80
 serotonergic control, 35
 peripheral neural pathways
 afferents
 efferents
 physiology, 72–3, 243
 spinal organization, 72
 supraspinal organization
 trigger for expulsion
 ejaculatory duct, 6
 ejaculatory dysfunction, 71, 243–4. *See*
 also ejaculation
 anejaculation, 73–4
 idiopathic, 244
 neurogenic, 244
 medical treatment, 75–7, 147
 assisted ejaculation procedures,
 76–7, 244–6
 pharmacotherapy, 75–6
 premature ejaculation, 95, 243
 retrograde ejaculation, 75, 244
 bladder sperm harvesting, 77,
 315–16
 retroperitoneal lymph node
 dissection effects, 73, 146, 244
 fertility preservation methods,
 146
 sperm retrieval, 315–16
 testosterone role, 97
 electroejaculation (EEJ), 142, 215–16,
 245–6, 316
 adolescents, 246
 cost-benefit analysis, 247
 following retroperitoneal lymph
 node dissection (RPLND), 247,
 316
 embryo cryopreservation, 232
 ethical and legal issues, 235–8
 balancing test, 235
 contemporaneous mutual consent
 approach, 235–6
 contractual approach, 235
 female cancer treatment and, 276–7
 embryo transfer, 338
 emotional responses, 190
 endometriosis, 330
 epididymis, 5–6
 examination, 46
 function, 5–6
 seminal fluid emission, 35, 36
 sperm maturation, 6, 18
 sperm storage, 5–6
 sperm transport, 6, 71–2
 innervation, 5
 percutaneous sperm aspiration, 215,
 250
 seminal components produced, 31
 surgical sperm retrieval, 250
 vascular supply, 5

- epididymitis, 298
- epispadias, 45
- erectile dysfunction (ED)
- epidemiology associated with infertility, 94–5
 - phosphodiesterase (PDE) inhibitor treatment, 80, 98–9, 155
- erection, 9. *See also* erectile dysfunction
- testosterone role in erectile function, 86–7, 96
- estradiol, sexual dysfunction and, 97
- ethical issues
- childhood cancer, 168–9, 232–5
 - fundamental right to procreate, 232–4
 - right not to reproduce, 240
 - postmortem sperm retrieval, 324–5
- ethylene glycol (EG), 216
- etoposide, 113, 116, 121
- Evans v. the United Kingdom, 236
- Ewing sarcoma, 125
- examination. *See* physical examination
- exogenous testosterone use. *See* testosterone
- family history, 43
- febrile illnesses, 42
- female cancers, 273–4
- fertility preservation, 273, 275–9
 - counseling, 274
 - embryo cryopreservation, 276–7
 - fertility-sparing surgery, 275–6
 - gonadal protection using drugs, 278–9
 - in-vitro culture of ovarian follicles, 278
 - oocyte cryopreservation, 277
 - ovarian tissue freezing, 277–8
 - ovarian tissue transplantation, 278
 - shielding, 275
 - stimulation protocols with breast cancer, 277
 - gonadotoxic effects of treatment, 274–5
 - chemotherapy, 274–5
 - radiotherapy, 275
- female infertility, 330–1
- endometriosis, 330
 - polycystic ovary syndrome (PCOS), 330
 - prognostic factors, 331
 - antral follicle count, 331
 - hormonal assays, 331
 - ovarian reserve testing, 331
 - tubal factor infertility, 330
 - unexplained infertility, 331
- Fertile Hope's Centers of Excellence Program, 183–4
- fertility preservation, 178
- barriers to discussion, 172–4, 259–61, 282–4
 - patient barriers, 173–4
 - time, 283
 - chemotherapy and, 145
 - childhood cancer and, 164–8, 256–9
 - embryo cryopreservation, 235–8
 - ethical and legal issues, 168–9, 232–5
 - need to clearly state intentions, 238–40
 - options, 257
 - sperm cryopreservation, 164, 235–8, 256–7
 - stem cell autotransplantation, 257–8
 - stem cell culture, 258–9
 - testicular tissue harvesting, 164–6
 - facilitating provider discussion, 174–5
 - female cancers, 273, 275–9
 - counseling, 274
 - embryo cryopreservation, 276–7
 - fertility-sparing surgery, 275–6
 - gonadal protection using drugs, 278–9
 - in-vitro culture of ovarian follicles, 278
 - oocyte cryopreservation, 277
 - ovarian tissue freezing, 277–8
 - ovarian tissue transplantation, 278
 - shielding, 275
 - stimulation protocols with breast cancer, 277
 - hormonal suppression, 166–8, 203–4
 - animal studies, 205–6
 - clinical trials, 206–8
 - relationship between animal and human studies, 208–9
 - importance for cancer patients, 224–7
 - interest in, 172
 - oncologist's responsibilities, 231–2
 - patient's options, 231–2
 - program development. *See* Fertile Hope's Centers of Excellence Program; Memorial Sloan–Kettering Cancer Center (MSKCC)
- psychological issues, 186–7
- countertransference issues, 192
 - psychological consultation, 190–1
 - psychosocial assessment, 189
 - radiation therapy and, 145
 - retroperitoneal lymph node dissection and, 146
 - spermatogonial transplantation, 209
- testicular cancer patients, 141–6
- cryopreserved sperm use, 142
 - following radical orchiectomy, 144–6
 - partial orchiectomy and, 142–3, 251
 - sperm banking prior to treatment, 141–2
 - sperm retrieval at orchiectomy, 143–4
- fertility re-establishment, 146–7
- fertilization, 335
- finasteride, 43
- fine-needle aspiration of the testis, 250
- fish oil consumption, 197–8
- flutamide, 84
- folic acid, 196–7
- follicle-stimulating hormone (FSH), 2, 19, 111
- as marker of Sertoli cell function, 111–12
 - azoospermia evaluation, 59
 - hypogonadism and, 81–2
 - management, 88
 - infertility treatment, 296
 - measurement, 293
 - oligospermia and, 52–3
 - prognostic value in female infertility, 331
 - regulation, 81
 - spermatogenesis and, 266
 - role as marker after chemotherapy, 116
 - testosterone relationships, 2
- freeze drying, 220
- fundamental right to procreate, 232–4
- gemcitabine, 113, 121
- germ cells, 13–14
- germ cell transplantation, 165–6, 226
 - in-vitro maturation, 166
- glioblastomas, 150, 152

Index

- gliomas, 152–5
 chemotherapy, 152
 immunotherapy, 154
 radiation therapy, 152
 effects on pituitary function, 154–5
 sildenafil effects on growth, 155
 temozolomide chemotherapy, 153–4
- glucocorticoids, 151–2
- GnRH. *See* gonadotropin-releasing hormone (GnRH)
- GnRH agonists, 84
 hormonal manipulation for fertility preservation, 167, 204
 animal studies, 205–6
 clinical trials, 206–8
 female cancers, 278–9
 relationship between animal and human studies, 208–9
- gonadotropin-releasing hormone (GnRH), 19, 111, 265. *See also* GnRH agonists
 hypogonadism management, 88, 295
 regulation, 19
 secretion, 1–2, 80
- graft versus host disease (GVHD), 134–5
- heart health, 195. *See also* dietary supplements
- hematopoietic stem cell transplantation (HSCT), 133
 allogeneic, 134
 autologous, 133
 fertility and, 135–7
 graft versus host disease (GVHD), 134–5
 process of, 133–5
 conditioning, 134
 graft, 133–4
 immunosuppression, 134
- hemizona assay, 55
- history taking. *See* infertility; *specific conditions*
- Hodgkin's lymphoma, 32, 44–5, 129–31
 chemotherapy effects, 83, 114–16, 129–31
 spermatogenesis and, 112
- homologous recombination, 15–16
- hormonal therapy, 121–2
- human chorionic gonadotropin (hCG), hypogonadism management, 88, 270, 295–6
- human menopausal gonadotropin (hMG), hypogonadism management, 88, 295–6
- human sperm preservation medium (HSPM), 217
- hydrocele, 46
- hypergonadotropic hypogonadism, 81. *See also* hypogonadism
- hyperprolactinemia, 97
 cranial radiotherapy effects, 155
 medical treatment, 297–8
- hypertension, 42
- hyperthyroidism, 97
- hyperviscous semen, 26
- hypogastric nerve, 35
- hypogonadism, 80, 266–7. *See also* androgen deficiency; testosterone
 body composition changes, 86
 bone mineral density and, 85–6
 cardiovascular effects of, 85
 causes, 81–4
 aging, 82–3
 cancer therapies, 83–4
 cognition and mood relationships, 86
 diagnosis, 87–8
 metabolic effects of, 84–5
 sexual function and, 86–7, 96–7
 testicular cancer and, 44
 treatment, 88–9, 269–70, 294
 clomiphene citrate, 294
 GnRH, 295
 hCG and hMG, 295–6
 varicocele and, 308–9
- hypogonadotropic hypogonadism, 82. *See also* hypogonadism
- hypospadias, 45
- hypothalamic–pituitary–gonadal (HPG) axis, 1, 19, 81, 265
 hormonal suppression for fertility preservation, 203–4
 animal studies, 205–6
 clinical trials, 206–8
 relationship between animal and human studies, 208–9
 spermatogenesis regulation, 111
- hypothalamus, 1–2
 GnRH secretion, 1–2
- hypothyroidism, 98
- hysterosalpingography (HSG), 330
- idiopathic anejaculation, 244
- idiopathic anorgasmia, 244
- ifosfamide, 116, 120
- imipramine, ejaculatory dysfunction treatment, 75–6
- immotile cilia syndrome, 42, 53
- immotile sperm, 28. *See also* asthenospermia
- immunomodulators, 121–2
- immunosuppression, 134, 299
- immunotherapy, gliomas, 154
- in-vitro fertilization (IVF), 329
 following postmortem sperm retrieval, 324–5
 legal issues, 325–6
 logistical issues, 325
 outcomes, 338–9
 sperm preparation techniques, 333
 versus intrauterine insemination, 332
- infertility, 39
 chemotherapy effects, 113, 136–7
 alkylating agents, 120
 platinum analogs, 120–1
 childhood cancer long-term effects, 161
 combined morbidity with sexual dysfunction, 94
 associated hormonal disorders, 96–8
 cancer and cancer therapy effects, 98
 epidemiology, 94–5
 pharmacotherapy effects, 98–101
 psychogenic factors, 95–6
 evaluation, 292–3
 goals, 39
 exogenous testosterone use effects, 267
 recovery after, 268–9
 female infertility
 endometriosis, 330
 etiologies, 330–1
 polycystic ovary syndrome (PCOS), 330
 prognostic factors, 331
 tubal factor infertility, 330
 unexplained infertility, 331
 hematopoietic stem cell transplantation (HSCT) effects, 135–7
 history, 39–45
 cancer and cancer therapies, 44–5
 childhood illnesses and conditions, 41–2

- family history, 43
 lifestyle and occupational history, 43–4
 medications, 43
 past surgical history, 42–3
 reproductive history, 40–1
 sexual dysfunction, 41
 systemic diseases, 42
 in cancer patients, 31–2
 medical treatment, 293–8
 androgens, 296–7
 antioxidant supplements, 297
 aromatase inhibitors, 295
 clomiphene citrate, 293–4
 GnRH, 295
 hCG and hMG, 295–6
 hyperprolactinemia treatment, 297–8
 immunological infertility, 299
 infectious and inflammatory infertility, 298–9
 nutraceuticals, 297
 recombinant FSH, 296
 tamoxifen, 294–5
 psychological reactions to, 284
 radiation therapy effects, 104–6
 animal data, 106–7
 gonadal shielding, 108
 human data, 107–8
 secondary infertility, 267
 sexual desire and satisfaction relationships, 95
 testicular cancer relationships, 140–1
- inguinal hernia repair, 43
- inhibin, 2, 13, 19
 as spermatogenesis marker
 after chemotherapy, 116
 following childhood cancer, 164
 spermatogenesis regulation, 2
- interferon alpha, 121
- International Index of Erectile Function, 87
- Internet resources, 181
- intracytoplasmic sperm injection (ICSI), 215, 249
 azoospermic patients, 314–15
 oocyte preparation, 336
 using freeze dried sperm, 220
- intratubular germ cell neoplasia (ITGCN), 142–3
- intrauterine insemination (IUI), 332.
See also donor insemination
 cost-benefit analysis, 247
 history of, 284
- sperm preparation techniques, 333
 using cryopreserved sperm, 223
 versus in-vitro fertilization, 332
- irinotecan, 121
- Kallmann syndrome, 42, 82
- Kartagener's syndrome, 42, 53
- karyotypic abnormalities, 60
- kinetochores, 17
- Klinefelter syndrome, 60, 82
- Krause–Finger corpuscles, 35
- lamotrigine, 151
- L-carnitine, 197
- legal issues
 childhood cancer, 168–9, 232–5
 need to clearly state intentions, 238–40
 postmortem sperm retrieval, 325–6
 sperm cryopreservation, 220–1
 versus embryo cryopreservation, 235–8
- letrozole, 277
- leukemia, 106, 131
- leukocytospermia, 31, 54, 299
 differential diagnosis, 54
 treatment, 54
- levetiracetam, 151
- Leydig cells, 2, 12–13
 radiation damage, 105, 256
- lifestyle factors, 43–4, 195. *See also*
 dietary supplements
- lomustine, 120
- low volume ejaculate, 51–2
- lubricants, 41
- luteinizing hormone (LH), 2, 19, 111, 265
 hypogonadism and, 81–2
 regulation, 81
 spermatogenesis and, 266
 testosterone relationships, 2, 19
 negative feedback, 2
- lymphoma. *See* Hodgkin's lymphoma;
 non-Hodgkin's lymphoma (NHL);
 primary central nervous system lymphoma
 (PCNSL)
- major histocompatibility complex (MHC), 134
- male contraceptive, 270
- male infertility. *See* infertility
- male sexual development, 266
- male sexual dysfunction (MSD). *See*
 sexual dysfunction
- Massachusetts Male Aging Study (MMAS), 94
- mechlorethamine, 115
- medial preoptic area (MPOA)
- mediastinum, 71
- medications, 43. *See also specific drugs*
 anejaculation and, 73–4
- meiosis, 15–19
- melphalan, 120
- Memorial Sloan–Kettering Cancer Center (MSKCC), 178–83
 fertility preservation program
 development, 179–80
 assessment, 180
 clinical expertise, 182
 clinical research, 183
 clinician education, 181–2
 clinician resources, 181
 evaluation, 183
 implementation, 182–3
 patient resources, 180–1
- meningiomas, 155, 156
- mental health professional
 collaborative role, 191–2
- mercury levels in seafood, 198
- mesterolone, 296
- metastases, central nervous system, 158
- methotrexate, 43, 113, 121, 157
- methylprednisolone, 299
- microsurgical epididymal sperm aspiration (MESA), 215
- micro-testicular sperm extraction (microTESE), 147, 215, 251, 316–19
- midodrine, ejaculatory dysfunction treatment, 76
- mitotic inhibitors, 121
- mitoxantrone, 115, 121
- monoclonal antibodies, 122
- moral judgments, 190
- multiple gestations, 339
- mumps, 41–2
- myotonic dystrophy, 42

Index

- National Health and Social Life Survey (NHLS), 94
- natural-cycle IVE, 277
- necrospemia, 28, 53
- neuroblastoma, 123
- neurogenic anejaculation, 244
- nilutamide, 84
- non-Hodgkin's lymphoma (NHL), 131.
See also primary central nervous system lymphoma (PCNSL)
- non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), 124
- nutraceuticals. *See* dietary supplements
- occupational exposures, 44
- oligodendrogliomas, 152
- oligospermia, 27, 52–3
androgen therapy, 268
differential diagnosis, 52
in cancer patients, 31
- omega-3 fatty acids, 197–8
- oocyte cryopreservation, 277
- oocyte retrieval, 276, 335–6
maturity assessment, 335
preparation for fertilization, 335–6
- oocytes, chemotherapy effects, 274
- orchietomy
partial, 142–3, 251
radical, fertility preservation following, 144–6
sperm retrieval during, 143–4, 251
- orchitis, 298
- organ donation, 323
- orgasm, 35
- osteosarcoma, 125
- ovarian follicle in-vitro culture, 278
- ovarian hyperstimulation syndrome (OHSS), 334, 339
risk minimization, 334–5, 339
- ovarian reserve testing, 331
- ovarian stimulation, 333–4. *See also* controlled ovarian stimulation
hyper-responding patient, 334–5
long agonist protocols, 333
poor responding patient, 335
short antagonist protocols, 334
- ovarian tissue freezing, 277–8
- ovarian tissue transplantation, 278
- ovarian transposition, 275
- ovary
chemotherapy gonadotoxic effects, 274–5
radiotherapy effects, 275
- oxaliplatin, 120
- oxcarbamazepine, 151
- oxytocin (OT), ejaculation regulation, 80
- pampiniform plexus, 3
- paragigantocellular nucleus (nPGi), 36
- paraphimosis, 45
- paraventricular hypothalamic nucleus (PVN), 36
- parenthood, meaning of, 324
- partial orchietomy, 142–3
- partial zona dissection (PZD), 336
- pediatric patients. *See* childhood cancer
- pelvic floor muscles, role in seminal fluid expulsion, 72
- pemetrexed, 121
- penile vibratory stimulation (PVS), 76–7, 142, 244–5
- penis, 7–9
erection, 9
neuroanatomy, 8–9
physical examination, 45–6
vascular supply, 7–8
- percutaneous embolization, varicocele, 306
- percutaneous epididymal sperm aspiration (PESA), 215, 250
- Peyronie's disease, 46
- phenytoin, 151
- phosphodiesterase-5 (PDE5) inhibitors, 98–100
- physical examination, 45–7
azoospermia, 59
digital rectal examination, 47
penis, 45–6
scrotum, 46–7
varicocele, 66
- pituitary gland, 80–1. *See also* hypothalamic-pituitary-gonadal (HPG) axis
cranial radiotherapy effects on function, 154–5
tumors, 155–6
- platinum analogs, 120–1. *See also specific drugs*
CNS tumor treatment, 123
- polycystic ovary syndrome (PCOS), 330
- polyspermia, 27
- postmortem sperm retrieval, 322
consent issues, 322–4
ethical issues, 324–5
legal issues, 325–6
logistical issues, 325
need for protocols, 326–7
- prednisolone, 115, 299
- prednisone, 115
- pre-implantation genetic diagnosis (PGD), 174, 337
- pre-implantation genetic screening (PGS), 337–8
- premature ejaculation, 243
epidemiology associated with infertility, 95
- primary central nervous system lymphoma (PCNSL), 156–7
chemotherapy, 157
methotrexate, 157
procarbazine, 157
vincristine, 157
- primary ciliary dyskinesia, 42, 53
- primidone, 151
- procarbazine, 114–15, 120, 157
- procreative right, 232–4
- progenitor spermatogonia, 13–14
- prolactin, 97, 298. *See also* hyperprolactinemia
prolactin-secreting adenomas, 156
- prolactinoma, 42, 82
- prostate cancer therapy, 84
- prostate gland, 7
examination, 47
role in seminal fluid emission, 37
seminal components produced, 31
- prostate specific antigen (PSA), 31
- prostatitis, 298–9
- pseudoephedrine, ejaculatory dysfunction treatment, 76
- psychological assessment, 188–9
- psychological consultation, 188–9
fertility preservation, 190–1
- psychological issues, 186
background, 186–7

- countertransference issues, 192
 mental health professional collaborative role, 191–2
 psychosocial and emotional factors, 187–8
- psychotropic drugs, anejaculation and, 74
- pyospermia, 31, 54
- radiation therapy, 45, 104
 brain tumors, 152
 childhood cancer, gonadotoxic effects, 162, 256
 cranial, effects on pituitary function, 154–5
 female cancers, 275
 fertility preservation, 145
 fertility re-establishment, 146–7
 gliomas, 154–5
 hypogonadism and, 83–4
 sperm quality and use following treatment, 315
 retrieval in azoospermic patients, 319
 spermatogenesis impact, 104–6
 animal data, 106–7
 gonadal shielding, 108
 human data, 107–8
 versus chemotherapy, 113
 testicular cancer, 144–5
- rapamycin inhibitors, 122
- reactive oxygen species (ROS)
 semen, 55
 varicocele and, 304
- recreational drug use, 43–4
- reproductive history, 40–1
- reproductive specialist identification resources, 181
- retrograde ejaculation, 75, 244
 bladder sperm harvesting, 77, 315–16
 retrograde semen analysis, 77
- retroperitoneal lymph node dissection (RPLND)
 ejaculatory dysfunction and, 73, 146, 244
 sperm retrieval, 315–16
 fertility restoration, 246–7
 cost-benefit analysis, 247
 electroejaculation, 247
 medical management, 246–7
 following radical orchiectomy, 145–6
 modifications for fertility preservation, 146
- rhabdomyosarcoma (RMS), 124
- rituximab, 157
- sacral parasympathetic nucleus (SPN), 35
- salpingitis, 330
- sarcomas
 bone sarcomas, 125
 Ewing sarcoma, 125
 osteosarcoma, 125
 soft-tissue sarcomas, 124
 rhabdomyosarcoma (RMS), 124
- scrotum, physical examination, 46–7
- Securin, 16
- seizures
 anti-epileptic drugs (AED), 150–1
 with brain tumors, 150
- selective serotonin reuptake inhibitors (SSRIs), 99–101
- selenium, 198–9
- semen. *See also* semen analysis (SA)
 cancer and cancer therapy impact on, 56
 collection techniques for sperm banking, 141–2, 215–16
 ejaculation induction, 246
 liquefaction, 26
 pH, 26
 reactive oxygen species (ROS) levels, 55
 screening, 220–1
 varicocele effects, 65
 viscosity, 26
 hyperviscous semen, 26
 volume, 25–6
 low volume ejaculate, 51–2
- semen analysis (SA), 23–5, 32–3. *See also* semen; *specific parameters*
 abnormal parameters, 51
 azoospermia, 59
 biochemical analysis, 31
 in cancer patients, 31–2
 macroscopic characteristics, 25–6
 morphology, 29
 microscopic characteristics, 26–31
 anti-sperm antibodies (ASA), 30–1
 computer-assisted sperm assessment (CASA), 28
 count and concentration, 26–7
 morphology, 28–9
 motility, 27–8
 other cell types, 31
 viability, 29–30
 viscosity, 26
- parameters and clinical significance, 24
 predictive parameters, 32
 reference values, 25
 retrograde semen analysis, 77
 sample collection, 25. *See also* sperm retrieval
 semen heterogeneity, 23–4
 standard criteria, 23
 technical considerations, 25
 varicocele and, 67
 viability, 30
- semen extenders, 217
- semenogelin, 31
- seminal vesicles, 6–7, 72
 role in seminal fluid emission, 35
 seminal components produced, 31
- seminiferous tubules, 3–4, 11, 71
- seminoma, 140. *See also* testicular cancer, radiation therapy, 144
- Separase, 16, 17
- serotonin, ejaculation regulation, 35
- Sertoli cells, 2, 4, 13
 chemotherapy effects, 115
 functional impairment, 111–12
- sex-hormone binding globulin (SHBG), 82–3, 266
- sexual dysfunction, 41, 94
 cancer and cancer therapy effects, 98
 epidemiology related to infertility, 94–5
 hormonal disorders and, 96–8
 hypogonadism relationships, 86–7, 96–7
 pharmacotherapy related to infertility, 98–101
 psychogenic sexual dysfunction and infertility, 95–6
- sickle cell disease (SCD), 42
- sildenafil, 98–9
 effects on glioma growth, 155
- situational anorgasmia, 244
- smoking, 43
- specialist identification resources, 181
- sperm
 agglutination, 26, 30–1, 53
 concentration, 26–7
 fertility relationship, 32
 nomenclature, 27
 cryopreservation. *See* cryopreservation of sperm

Index

- sperm (*cont.*)
 DNA integrity tests, 55–6
 epididymal storage, 5–6
 flagellum, 18–19
 function tests, 54–5
 head, 18
 maturation, 6, 18
 morphological analysis, 28–9. *See also* teratospermia
 excess residual cytoplasm, 29
 fertility relationship, 32
 head shape defects, 29
 neck and mid-piece defects, 29
 tail defects, 29
 motility, 27–8. *See also* asthenospermia
 fertility relationship, 32
 immotile sperm, 28
 lubricant effects, 41
 non-progressive motility, 28
 progressive motility, 28
 nucleus, 18
 transport through epididymis, 6
 viability, 30
 assessment, 29–30, 55
- sperm banking, 141, 172. *See also* cryopreservation of sperm; fertility preservation
 barriers to discussion, 172–4, 225
 finding sperm banks, 283
 importance for cancer patients, 224–7
 sperm collection techniques, 141–2. *See also* sperm retrieval
 testicular cancer patients, 141–2
 tracking, 221
- sperm chromatin structure assay (SCSA), 55
- sperm count, 26–7. *See also* azospermia; oligospermia
 fertility relationship, 32
- sperm donation, 284. *See also* donor insemination
 cultural differences, 285
 donor guidelines, 222, 285
 history of, 284–5
 payment, 285
 screening, 285
- sperm penetration assay (SPA), 55
- sperm retrieval. *See also* electroejaculation (EEJ); semen analysis (SA)
 at orchiectomy, 143–4, 251
 azospermic patients
 following chemotherapy, 316–19
 following radiotherapy, 319
- bladder sperm harvesting, 77, 315–16
 childhood cancers, 257
 collection techniques for
 cryopreservation, 141–2
 following retroperitoneal or pelvic surgery, 315–16
 percutaneous testicular and epididymal extraction, 250
 postmortem retrieval, 322
 consent issues, 322–4
 ethical issues, 324–5
 legal issues, 325–6
 logistical issues, 325
 need for protocols, 326–7
 surgical retrieval of testicular sperm, 250–1
 micro-testicular sperm extraction (microTESE), 147, 251, 316–19
 testicular sperm extraction (TESE), 147
 surgical retrieval of vasal or epididymal sperm, 250
 terminally ill patients, 322
 consent issues, 322–4
 ethical issues, 324–5
 testicular cancer patients, 251–3
- sperm wash, 333
- spermatic veins, 64–5
- spermatids, 17–18
 radiation effects, 105
- spermatocytes, 4, 13
- spermatocytogenesis, 13
- spermatogenesis, 4–5, 13–19, 105, 110–12
 cancer effects, 31–2, 112–13
 chemotherapy effects, 113, 255–6
 alkylating agents, 120
 platinum analogs, 120–1
 gonadal toxicity model, 203
 hormonal suppression for fertility preservation, 166–8, 203–4
 animal studies, 205–6
 clinical trials, 206–8
 relationship between animal and human studies, 208–9
 meiosis, 15–19
 radiation therapy effects, 104–6, 113
 animal data, 106–7
 gonadal shielding, 108
 human data, 107–8
 recovery after exogenous testosterone use, 268–9
 regulation, 19
 negative feedback, 2
 requirements for, 266
- spermatogonia, 4, 13, 110–11. *See also* spermatogenesis
 chemotherapy effects, 113
 commitment to spermatogenesis, 13–14
 division patterns, 14–15
 gonadal toxicity model, 203
 radiation effects, 105
 animal data, 106–7
 recovery, 105–6
- spermatogonial stem cells, 14, 105. *See also* stem cell transplantation
 stem cell culture, 258–9
- spermatogonial transplantation, 209
- spermatotoxic agents, 43
- spermatozoa, 18. *See also* sperm
- spermiogenesis, 5, 13, 111
- spinal cord injury (SCI)
 anejaculation and, 73
 electroejaculation, 247
 penile vibratory stimulation (PVS), 76–7
- spinal cord tumors, 157–8
- stanazolol, 268
- stem cell culture, 258–9
- stem cell transplantation, 131–2. *See also* hematopoietic stem cell transplantation (HSCT)
 childhood cancer management, 257–8
 reduced dose intensity (RDI)
 transplant, 132
- streptozocin, 120
- stress, sexual dysfunction and, 95–6
- subparafascicular thalamus (SPFp), 36
- surgical castration, 84
- surgical history, 42–3
- surveillance, following radical orchiectomy, 144
- tamoxifen
 breast cancer treatment, 277
 male infertility treatment, 294–5
- taxanes, 121
- temozolomide, 120
 effects on fertility, 153–4
 glioma treatment, 152–4
- Ten-step circular process model, 191–2
- teratospermia, 29, 53–4
 differential diagnosis, 53

- terminally ill patients, 322. *See also* postmortem sperm retrieval consent issues, 322–4 ethical issues, 324–5
- TEST yolk buffer (TYB), 217
- testicular artery, 3, 5
- testicular biopsy, 225, 250
- testicular cancer, 44, 104, 140 cancer therapy effects, 83 chemotherapy, 116, 145 radiation therapy, 144–5 retroperitoneal lymph node dissection (RPLND), 145–6 fertility preservation, 141–6 cryopreserved sperm use, 142 following radical orchiectomy, 144–6 partial orchiectomy and, 142–3, 251 special considerations, 251–3 sperm banking prior to treatment, 141–2 sperm retrieval at orchiectomy, 143–4, 251 germ cell tumors (GCTs), 140–3 infertility relationships, 140–1
- testicular dysgenesis syndrome, 60, 104
- testicular failure. *See* hypogonadism
- testicular sperm aspiration (TESA), 215
- testicular sperm extraction (TESE), 147 azoospermia and, 61
- testicular tissue harvesting, 164–6, 225–6, 258–9 germ cell in-vitro maturation, 166 germ cell transplantation, 165–6, 226
- testicular torsion, 41
- testicular trauma, 41
- testicular vein, 3
- testis, 2–5 blood–testis barrier, 13 examination, 46 fine-needle aspiration, 250 gonadal toxicity model, 203 hormonal suppression for fertility preservation, 166–8, 203–4 animal studies, 205–6 clinical trials, 206–8 relationship between animal and human studies, 208–9 internal organization, 3–4 macroscopic anatomy, 11 microscopic anatomy, 12–13 size, 11 spermatogenesis, 4–5 surgical sperm retrieval, 250–1 varicocele effects, 65 vascular supply, 3, 11
- testolactone, 295
- testosterone, 19, 81. *See also* androgen deficiency; hypogonadism aging effects, 82 as male contraceptive, 270 body composition and, 86 cognitive function relationships, 86 depression relationships, 86 exogenous testosterone use, 265 infertility and, 267 rebound therapy, 296–7 spermatogenesis recovery after, 268–9 types of supplementation, 268 FSH relationships, 2 levels, 12, 265 diurnal rhythm, 266 measurement, 87–8, 293 raising endogenous levels, 269–70 varicolectomy and, 308–9 LH relationships, 2, 19, 81 negative feedback, 2 male sexual development and, 266 oligospermia and, 52–3 rebound therapy, 268 production, 265 secretion, 12 sexual function relationships, 86–7, 96–7 spermatogenesis regulation, 19, 111, 266 systemic effects, 85 varicocele effects, 65
- testosterone replacement therapy, 84, 268 hypogonadism management, 88, 89 infertility and, 101
- thyroid dysfunction, 97–8
- topoisomerase inhibitors, 121
- topotecan, 121
- trabeculae, 7
- transurethral resection of the ejaculatory ducts (TURED), 61
- tricyclic antidepressants, 43
- tubal factor infertility, 330
- tuberculosis, 42
- tunica albuginea, 7
- tyrosine kinase inhibitors, 122
- ultrasonography, varicocele investigation, 66–7
- urethra role in seminal fluid expulsion, 35
- urethral manipulation syndrome, 46
- urethritis, 298
- uterine irradiation, 275
- vaginal irradiation, 275
- valproic acid, 151
- varicocele, 47, 52, 64, 66, 303–4 clinical features, 65 considerations with cancer, 67–8 diagnosis, 304 epidemiology, 303 evaluation, 66–7 pathophysiology, 64–5, 304 treatment, 68, 305–6, 307 indications, 67–8, 305 percutaneous embolization, 306 surgery, 305–6
- varicolectomy, 305–6 azoospermia and, 307–8 efficacy, 306–7 hypogonadism and, 308–9 reproductive technology and, 309–10
- vas deferens, 6, 72 absence of, 46–7 examination, 46–7 role in seminal fluid emission, 35 surgical sperm retrieval, 250
- vasectomy, 43
- vinblastine, 115
- Vinca alkaloids, 121
- vincristine, 115, 157
- vitamin C, 199–200, 297 sources, 199
- vitamin E, 198–9, 297
- vitrification oocytes, 277 ovarian tissue, 278 sperm, 219–20
- Wilms' tumor, 123–4
- Wolffian duct, 7
- Y-chromosome microdeletions, 60
- Young's syndrome, 42
- zona pellucida (ZP), 336